Prognostic factors in colorectal cancer evolution

Romanian Journal of Morphology and Embryology

Volumn 52, Issue SUPPL. 1, 2011, Pages 373-377

  Strambu V ^a   Iorga, C ^a   Radu, P ^a   Stoian, S ^a   Puscu C ^a   Bratucu M ^a   Garofil, D ^a   Popa, F L ^a  

^a Department of General Surgery   (Romania)

Author keywords

Colorectal cancer; Molecular markers; Prognostic factors; TME

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; COLORECTAL TUMOR; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE;

CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 79953137995     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C, CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers, Anticancer Res, 2002, 22(4):2311-2316.
2. Zheng CX, Zhan WH, Zhao JZ, The prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 62-4 in patients with colorectal cancer, World J Gastroenterol, 2001, 3:431-434.
3. Huang M, Tang D, Li B, Evaluation of biliary CEA in the diagnosis of colorectal cancer with liver metastases, Zhonghua Zhong Liu Za Zhi, 1999, 21(1):45-47.
4. Turoldo A, Balani A, Scaramucci M, Babic F, Guidolin D, Liguori G, Prognostic importance of preoperative CEA in patients with colorectal cancer, Chir Ital, 2002, 54(4):469-476.
5. Spila A, Ferroni P, Cosimelli M, D'alessandro R, Abbolito Mr, Mariotti S, Aloe S, Carone Md, Graziano F, Tedesco M, Martini F, Mancini R, Stigliano V, Roselli M, Guadagni F, Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation, Anticancer Res, 2001, 21(2B):1263-1270.
6. Wichmann MW, Lau-Werner U, Müller C, Hornung HM, Stieber P, Schildberg FW; COLORECTAL CANCER STUDY GROUP, Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer, Anticancer Res, 2000, 20(6D):4953-4955.
7. Yamamoto H, Miyake Y, Noura S, Ogawa M, Yasui M, Ikenaga M, Sekimoto M, Monden M, Tumor markers for colorectal cancer, Gan To Kagaku Ryoho, 2001, 28(9):1299-1305.
8. Allende T, García Muñiz JL, Vizoso F, Del Casar JM, Raigoso P, Llana B, Serra C, Zeidán N, García-Morán M, Roiz C, Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer, Rev Esp Med Nucl, 2001, 20(5):358-364.
9. Holubec Jr L, Topolcan O, Pikner R, The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence, Anticancer Res, 2000, 20(6D):5237-5244.
10. Moura RM, Matos D, Galvão Filho MM, D'ippólito G, Sjzenfeld J, Giuliano LM, Value of CEA level determination in gallbladder bile in the diagnosis of liver metastases secondary to colorectal adenocarcinoma, Sao Paolo Med J, 2001, 119(3):110-113.
11. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS, Chen Pm, CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer, Hepatogastroenterology, 2002, 49(43):160-164.
12. Macfarlane JK, Ryall RD, Heald RJ, Mesorectal excision for rectal cancer, Lancet, 1993, 341(8843):457-460.
13. Quirke P, Scott N, The pathologist's role in the assessment of local recurrence in rectal carcinoma, Surg Oncol Clin North Am, 1992, 1:1-17.
14. Moynihan BG, The surgical treatment of cancer of the sigmoid lexure and rectum: with special reference to the principles to be observed, Surg Gynecol Obstet, 1908, 6:436-438.